GRI Bio (GRI) reported interim biomarker results from its ongoing Phase 2a study evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis. Additionally, management participated in a Virtual Investor “What This Means” segment to discuss the interim biomarker data.The IDMC has examined the change from baseline biomarkers from the first 12 subjects at 2 weeks and determined the change from baseline in PRO-C3 of GRI-0621-treated patients compared to placebo patients is suggestive of anti-fibrotic effect. Based on the available interim data reviewed, the IDMC has recommended the Phase 2a study evaluating GRI-0621 to continue as planned as there are no safety concerns seen to date.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRI:
- GRI Bio announces enrollment update for Phase 2a study of GRI-0621
- Promising Prospects for GRI Bio: Matthew Keller’s Buy Rating on GRI-0621 Amid Positive Phase 2a Safety Data
- GRI Bio reports interim 2-week safety results from Phase 2a study of GRI-0621
- GRI Bio announces the granting of two global patents for Europe, Japan
- GRI Bio files to sell common stock, warrants, no amount given